<DOC>
	<DOCNO>NCT00240565</DOCNO>
	<brief_summary>This study characterize activity Tositumomab Iodine I 131-Tositumomab patient relapsed indolent non-Hodgkin 's Lymphoma progress follow treatment rituximab .</brief_summary>
	<brief_title>Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Inclusion criterion : Patients must evidence persistent progressive follicular grade , 1 , 2 3 marginal zone Bcell nonHodgkin 's lymphoma . Must receive least two prior course systemic treatment include least one treatment rituximab ( lymphoma must progress recent systemic chemotherapy treatment ) . Must evidence lymphoma express CD20 antigen adequate renal hepatic function . Exclusion criterion : Received chemotherapy , radiation therapy , immunosuppressant cytokine treatment within 4 week prior study entry . Have active obstructive hydronephrosis . Had prior autologous hematopoietic stem cell transplant allogenic stem cell transplant . Have active infection require IV antibiotic . Have brain leptomeningeal metastasis . Had previous allergic reaction iodine , previously receive radioimmunotherapy currently receive approve experimental anticancer drug . Patients pregnant breast feeding , know HIV infection , Human antimurine antibody ( HAMA ) positive . Other criterion evaluate screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>BEXXAR</keyword>
	<keyword>non-Hodgkin 's Lymphoma</keyword>
	<keyword>tositumomab</keyword>
	<keyword>I-131</keyword>
</DOC>